ARCH Venture Partners IX Overage, L.P. is 10% at Vir Biotechnology, Inc. (VIR). They have made 1 open-market trade across 1 company since 2026, most recently 2026-03-06.
CIK 0001723172
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $12.5M since 2026, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VIR | 10,112,845 | $100.8M |
| BEAM | 4,121,519 | $96.8M |
| LYEL | 1,426,528 | $11.6M |
| KRTX | 918 | $303K |
| Total | $209.5M |
Shares reported on the most recent Form 4, priced at the 2026-03-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LYEL | BUY | 2026-03-06 | 2026-03-09 | $25.61 | $12.5M | -21.1% | -12.0% | -53.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.